News | March 06, 2014

TAVR Implant Count Reaches 100 at Birmingham Hospital

TAVR Heart valve repair Hybrid OR Edwards Lifesciences Sapien

March 6, 2014 — At age 88, Lena M. Smith visited her doctor, Larry Hunt, M.D., at the University of Alabama at Birmingham to find out why her energy level had diminished. 

Hunt, a primary care physician and assistant professor in the UAB School of Medicine, detected a heart murmur, and an echocardiogram confirmed aortic stenosis. Smith needed her aortic valve replaced. UAB Heart and Vascular Services cardiothoracic surgeon Spencer Melby, M.D., and interventional cardiologist Seun Alli, M.D., scheduled Smith for the minimally invasive Edwards Lifesciences Sapien transcatheter heart valve replacement system surgery. She became the 100th patient to undergo the procedure at UAB Hospital since the program began in August 2012.   

 “I feel great — amazing,” Smith said. “I’m a satisfied customer and ready to get moving again.” 

UAB is home to Alabama’s largest and oldest heart valve disease treatment program and is one of just a few in the state trained to offer the Edwards Lifesciences TAVR — the only transcatheter aortic valve replacement therapy approved for commercial use in the United States. UAB performs more valve procedures annually than anyone in the state and has since the inception of its program. 

UAB completed its 100th TAVR transplant in 18 months. Many programs around the country complete approximately 50 TAVR procedures in the same time period. 

“We have had great success since we began doing the TAVR procedure, and a big reason for that is that we have a tremendous team in place,” Alli said. “In many cases, these are really sick people who don’t have a lot of other options. Open-heart surgeries just aren’t possible because of the age or other medical issues of the patient in most cases. But we’ve done 100 of these cases with minimum complications, and we’ve had very good outcomes. We’ve seen that when they come back to clinic for follow-up they are symptomatically better and have an improved quality of life. 

The big advantage to the TAVR procedure is that surgeons can replace valves without open-heart surgery. 

For more information: www.uab.edu

Related Content

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Overlay Init